Health Care Equipment

Axogen

Axogen released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 61.46 M (forecast USD 57.77 M), actual EPS USD -0.38 (forecast USD -0.3857)

AxoGen Reports 27% Q1 Revenue Growth and Adjusted Net Income Turned Profitable

Axogen to Release FY2026 Q1 Earnings on April 28 Pre-Market EST, Forecast Revenue USD 57.77 M, EPS USD -0.3857

Axogen released FY2025 Q4 earnings on February 24 Pre-Market (EST), actual revenue USD 59.9 M (forecast USD 59.9 M), actual EPS USD -0.2803 (forecast USD -0.0128)

Axogen released FY2025 earnings on February 24 Pre-Market (EST), actual revenue USD 225.21 M (forecast USD 225.22 M), actual EPS USD -0.3409 (forecast USD -0.0671)

Axogen to Release FY2025 Q4 Earnings on February 24, 2026, Pre-Market EST; Forecast Revenue USD 59.9 M, EPS USD -0.0157

AxoGen Inc Expands Common Stock Offering to $124 Million

Axogen Inc. Outlines Strategic Priorities to Establish Standard of Care in Nerve Repair

Axogen Inc. Predicts 20.2% Revenue Growth in 2025

Axogen released FY2025 Q3 earnings on October 29 Pre-Market EST, actual revenue USD 60.08 M (forecast USD 56.9 M), actual EPS USD 0.0099 (forecast USD -0.0266)

Axogen released FY2025 9 Months earnings on October 29 Pre-Market (EST), actual revenue USD 165.3 M, actual EPS USD -0.0648

Axogen Inc. Outlines Growth Strategy for Nerve Repair Solutions

Takkinen Recommends Healthcare Industry Stocks

Axogen to Release FY2025 Q3 Earnings on October 29 Pre-Market EST, Forecast Revenue USD 56.9M, EPS USD -0.0266

Cronin recommends AxoGen stock with 31.51% upside potential

Axogen released FY2025 Semi-Annual earnings on August 5 Pre-Market (EST), actual revenue USD 105.22 M, actual EPS USD -0.0713

Axogen released FY2025 Q2 earnings on August 5 Pre-Market (EST), actual revenue USD 56.66 M (forecast USD 52.61 M), actual EPS USD 0.0099 (forecast USD -0.042)

Axogen to Release FY2025 Q2 Earnings on August 5, Pre-Market EST; Forecast Revenue USD 52.61 M, EPS USD -0.042

Axogen Inc. holds annual general meeting to elect board members

Axogen Director William P. Burke Disposes of Common Stock

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

AXGN

Stephens Investment Management Group LLC acquired a new stake in AxoGen, Inc. (NASDAQ:AXGN) during Q4, purchasing 154,085 shares valued at approximately $5 million. Other institutional investors also increased their holdings. Analyst ratings for AxoGen vary, with a consensus rating of 'Moderate Buy' and an average price target of $46.50. Recent insider sales were reported, and AxoGen's stock opened at $40.99, with a market cap of $2.18 billion.

Market Beat

Stephens Investment Management Group LLC Acquires New Stake in AxoGen, Inc. $AXGN

AxoGen's President and CEO, Michael Dale, affirmed the company's focus on peripheral nerve repair, highlighting recent reimbursement wins as potentially beneficial, though their impact remains unquantified. He noted that Aetna is the last major payer yet to decide on coverage. AxoGen reported a 27% growth in Q1 and anticipates at least 20% growth for the year, maintaining a long-term view of double-digit growth. The company expects gross margins to bottom in Q2 due to a transition in product types, with improvements anticipated in 2027.

AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam

Axogen, Inc. reported a Q1 2026 revenue of $61.46 million, up from $48.56 million a year prior, despite a wider net loss of $19.58 million. The company raised its 2026 revenue outlook to at least $270 million, projecting 20% growth and a gross margin of 74-76%. This shift highlights both potential revenue catalysts and risks related to operating costs and execution. Analysts have varying fair value estimates for Axogen, ranging from $31.42 to $50.78 per share, reflecting differing opinions on the stock's future performance.

Simplywall

NVIDIA

Microsoft

NVIDIA Corporation

Axogen (AXGN) Is Up 10.3% After Raising 2026 Revenue Outlook Despite Wider Q1 Loss – Has The Bull Case Changed?

Axogen (AXGN) reported Q1 2026 revenue of US$61.5 million with a basic EPS loss of US$0.38, widening its net loss to US$19.6 million. Despite a revenue increase from US$48.6 million in Q1 2025, the company struggles with profitability, showing a net loss of US$31.5 million over the trailing 12 months. The stock trades at a high P/S ratio of 9.2x, raising concerns about valuation and dilution amidst ongoing losses. Investors are advised to consider the balance of optimism and caution in Axogen's financial outlook.

Axogen (AXGN) Q1 Loss Of US$0.38 EPS Tests Bullish Margin Improvement Narrative

ARKG

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Ark Genomic Revolution ETF

Nasdaq

Axogen (AXGN) Q1 2025 Earnings Transcript

Axogen, Inc. (AXGN) reported a 26.6% revenue growth for Q1 2026, reaching $61.46 million, and raised its full-year revenue guidance to at least $270 million. Despite a net loss of $19.58 million, adjusted net income improved to $4.1 million. Following the announcement, AXGN's stock surged 9.02% to $42.94. The company has cash and investments totaling $103.6 million as of March 31, 2026. CEO Michael Dale expressed satisfaction with the company's performance and strategic progress.

Axogen Q1 Revenue Jumps; Lifts 2026 Revenue Guidance; Stock Up

Axogen (NASDAQ:AXGN) reported Q1 2026 revenue of $61.5 million, a 26.6% increase from Q1 2025, driven by growth in all target markets. The company raised its full-year guidance, expecting at least 20% revenue growth and a gross margin of 74-76%. Axogen is focused on making peripheral nerve repair a standard of care and is progressing on its strategic priorities, including market development and commercial expansion. The earnings call included forward-looking statements regarding financial guidance and business strategy.

benzinga_article

Full Transcript: Axogen Q1 2026 Earnings Call

Health care stocks showed mixed performance in premarket trading on Tuesday. The State Street Health Care Select Sector SPDR ETF (XLV) rose by 0.6%, while the iShares Biotechnology ETF (IBB) fell by 0.01%. Novartis (NVS) shares dipped less than 1% after reporting lower Q1 earnings. Axogen (AXGN) saw a premarket increase of over 9% following a swing to Q1 adjusted earnings. Conversely, Zimmer Biomet (ZBH) dropped more than 6% despite reporting higher Q1 results and announcing the departure of its CFO.

Axogen(AXGN.US)